Show simple item record

dc.contributor.authorAhrens, M
dc.contributor.authorEscudier, B
dc.contributor.authorBoleti, E
dc.contributor.authorGrimm, MO
dc.contributor.authorGoupir, MG
dc.contributor.authorBarthelemy, P
dc.contributor.authorGravis, G
dc.contributor.authorBedekes, J
dc.contributor.authorIvanyi, P
dc.contributor.authorPanic, A
dc.contributor.authorZschabitz, S
dc.contributor.authorNeyrieru, S
dc.contributor.authorMellado, B
dc.contributor.authorBie, A
dc.contributor.authorWadell, Tom
dc.contributor.authorMaroto, JP
dc.contributor.authorRetz, M
dc.contributor.authorBoegemann, M
dc.contributor.authorRottey, S
dc.contributor.authorHaanen, J
dc.contributor.authorOosting, S
dc.contributor.authorCastellano, D
dc.contributor.authorHartmann, A
dc.contributor.authorBergmann, L
dc.date.accessioned2020-04-22T07:25:13Z
dc.date.available2020-04-22T07:25:13Z
dc.date.issued2020en
dc.identifier.citationAhrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, et al. A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast). Oncology Research and Treatment. 2020;43:226-en
dc.identifier.urihttp://hdl.handle.net/10541/622943
dc.language.isoenen
dc.titleA randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniklinik Frankfurt, Med. Klinik II, Frankfurten
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record